June 27, 2023 Comments Off on New patent for Boehringer Ingelheim drug GLYXAMBI Posted in: Patent Added Annual Drug Patent Expirations for GLYXAMBI Glyxambi is a drug marketed by Boehringer Ingelheim and is included in one NDA. It is available from one supplier. There are thirteen patents…
The post New patent for Boehringer Ingelheim drug GLYXAMBI appear…
June 27, 2023 Comments Off on New patent for Boehringer Ingelheim drug JARDIANCE Posted in: Patent Added Annual Drug Patent Expirations for JARDIANCE Jardiance is a drug marketed by Boehringer Ingelheim and is included in one NDA. It is available from five suppliers. There are seven patents…
The post New patent for Boehringer Ingelheim drug JARDIANCE appe…